Showing results (131-140 of 223) with videos related to

Sort By:
Pageof 23
Journal of Acquired Immune Deficiency Syndromes (1999)|June 28, 2017
Active HCV Replication but Not HCV or CMV Seropositive Status Is Associated With Incident and Prevalent Type 2 Diabetes in Persons Living With HIVAndrea De Luca, Patrizia Lorenzini, Antonella Castagna, et al.
Journal of Global Antimicrobial Resistance|November 19, 2022
Real world efficacy of dolutegravir plus lamivudine in people living with HIV with undetectable viral load after previous failuresRoberta Gagliardini, Patrizia Lorenzini, Alessandro Cozzi-Lepri, et al.
The Journal of Antimicrobial Chemotherapy|May 29, 2020
In vitro susceptibility to fostemsavir is not affected by long-term exposure to antiviral therapy in MDR HIV-1-infected patientsFrancesco Saladini, Alessia Giannini, Federica Giammarino, et al.
BMC Infectious Diseases|March 8, 2017
Systemic inflammation-based scores and mortality for all causes in HIV-infected patients: a MASTER cohort studyElena Raffetti, Francesco Donato, Salvatore Casari, et al.
The Journal of Antimicrobial Chemotherapy|December 23, 2019
Virological response and retention in care according to time of starting ART in Italy: data from the Icona Foundation Study cohortAntonella d'Arminio Monforte, Alessandro Tavelli, Alessandro Cozzi-Lepri, et al.
The Lancet. HIV|October 4, 2019
Bone mineral density in virologically suppressed people aged 60 years or older with HIV-1 switching from a regimen containing tenofovir disoproxil fumarate to an elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide single-tablet regimen: a multicentre, open-label, phase 3b, randomised trialFranco Maggiolo, Giuliano Rizzardini, François Raffi, et al.
Open Forum Infectious Diseases|May 22, 2026
Risk of Developing Low-Level Viral Rebound Among People With HIV Receiving 2- or 3-Drug Regimens: A Case-Control Study Nested in the ICONA CohortAlessandra Vergori, Adriana Cervo, Ashley Roen, et al.
The New Microbiologica|January 22, 2024
Optimizing the antiretroviral treatment focusing on long-term effectiveness and a person-centered approach. Consensus Guidance Using a Delphi ProcessFranco Maggiolo, Sergio Lo Caputo, Stefano Bonora, et al.
Plos One|October 8, 2016
Long-Term Durability of Tenofovir-Based Antiretroviral Therapy in Relation to the Co-Administration of Other Drug Classes in Routine Clinical PracticeSilvia Costarelli, Alessandro Cozzi-Lepri, Giuseppe Lapadula, et al.
The Journal of Antimicrobial Chemotherapy|May 27, 2005
Exploratory analysis for the evaluation of lopinavir/ritonavir-versus efavirenz-based HAART regimens in antiretroviral-naive HIV-positive patients: results from the Italian MASTER CohortCarlo Torti, Franco Maggiolo, Andrea Patroni, et al.
Pageof 23